Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
基本信息
- 批准号:7126935
- 负责人:
- 金额:$ 30.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-28 至 2010-07-31
- 项目状态:已结题
- 来源:
- 关键词:antidepressantsbenzodiazepinescatecholaminesclinical researchcombination chemotherapycomorbiditycooperative studydisease /disorder onsetdisease /therapy durationdrug metabolismdrug resistancegenetic polymorphismhuman subjecthuman therapy evaluationmental disorder chemotherapypatient oriented researchpharmacogeneticsphobiaspsychopharmacologyserotonin inhibitorsertralinevenlafaxine
项目摘要
DESCRIPTION (provided by applicant): Social anxiety disorder (also referred to as social phobia) is among the most common psychiatric conditions in the community, and is associated with significant distress and dysfunction in affected individuals. This combination of high prevalence (conservatively 4-5%) and substantial attendant morbidity in generalized social anxiety disorder (GSAD) positions it as a serious public health problem. Although currently available treatments for GSAD are efficacious, most patients remain residually symptomatic after initial psychosocial or psychopharmacological intervention. Clinicians regularly face the question of what to do next for these patients, but there are no empirically derived data available to guide clinical practice regarding the relative benefits of "next step" strategies to improve outcome. The absence of such data is a substantial barrier to advancing knowledge and patient care in this area.
Given the extensive use of medication treatment in psychiatric and primary care settings and the relative dearth of availability of empirically based psychosocial therapies outside of rarified research settings, we are proposing a 5-year study to systematically assess the relative efficacy of alternate pharmacologic treatment strategies in patients with GSAD remaining symptomatic despite initial SSRI pharmacotherapy. In addition, we will examine predictors of response (e.g., age at onset, duration of illness, comorbidity) to initial SSRI therapy and predictors of differential response to the strategies under study. We will also examine whether polymorphisms in well-studied genes that influence serotonin and/or catecholamine metabolism influence response to treatment in GSAD. The study comprises a double-blind, placebo controlled, randomized trial to compare the relative benefits of the addition of a benzodiazepine (clonazepam), or a switch to an alternative antidepressant (venlafaxine extended-release), for patients with GSAD who remain symptomatic after a 10-week trial of sertraline alone. One hundred sixty-three patients will be entered at each of the three sites (total N = 490): the Center for Anxiety and Traumatic Stress Related Disorders at the Massachusetts General
Hospital, the Anxiety Disorders Program at the University of California San Diego, and the Anxiety Disorders Clinic at McMaster University. The CMSD mechanism is being employed to take advantage of each of the sites' previous experience with the systematic evaluation and treatment of individuals with GSAD and to ensure timely recruitment of an adequate number of subjects.
This study will provide systematic, prospectively derived data in an understudied area - that of improving outcomes in patients with anxiety disorders. It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population.
描述(由申请人提供):社交焦虑障碍(也被称为社交恐惧症)是社区中最常见的精神疾病之一,与受影响个体的显著痛苦和功能障碍有关。广泛性社交焦虑症(GSAD)的高患病率(保守估计为4-5%)和伴随而来的大量发病率使其成为一个严重的公共卫生问题。虽然目前可用的治疗方法对GSAD是有效的,但大多数患者在最初的社会心理或精神药物干预后仍有残余症状。临床医生经常面临这样的问题:下一步该为这些患者做什么,但没有经验推导的数据来指导临床实践,关于“下一步”策略的相对好处,以改善结果。缺乏此类数据是推进这一领域知识和患者护理的重大障碍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MURRAY B. STEIN其他文献
MURRAY B. STEIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MURRAY B. STEIN', 18)}}的其他基金
Endocannabinoid System Engagement and Clinical Symptom Change with Cannabidiol for Social Anxiety Disorder
大麻二酚治疗社交焦虑症的内源性大麻素系统参与和临床症状变化
- 批准号:
10552048 - 财政年份:2022
- 资助金额:
$ 30.17万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8520396 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8307195 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8333455 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
8110675 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
Modifiable Risk and Protective Factors for Suicidal Behaviors in the US Army
美国陆军自杀行为的可改变风险和保护因素
- 批准号:
7894891 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
药理学功能磁共振成像鉴定新型抗焦虑药:人体生物测定
- 批准号:
7442252 - 财政年份:2006
- 资助金额:
$ 30.17万 - 项目类别:
Pharmacological fMRI to Identify New Anxiolytics: A Human Bioassay
药理学功能磁共振成像鉴定新型抗焦虑药:人体生物测定
- 批准号:
7263148 - 财政年份:2006
- 资助金额:
$ 30.17万 - 项目类别:
PharmacofMRI to Identify New Anxiolytics: A Human Bioassay
PharmacofMRI 鉴定新型抗焦虑药:人体生物测定
- 批准号:
7147829 - 财政年份:2006
- 资助金额:
$ 30.17万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7688141 - 财政年份:2005
- 资助金额:
$ 30.17万 - 项目类别:
相似海外基金
Pharmacotherapy of Cannabinoid Withdrawal: Pre-Clinical Studies
大麻素戒断的药物治疗:临床前研究
- 批准号:
7876875 - 财政年份:2009
- 资助金额:
$ 30.17万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7284786 - 财政年份:2005
- 资助金额:
$ 30.17万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7485187 - 财政年份:2005
- 资助金额:
$ 30.17万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7126933 - 财政年份:2005
- 资助金额:
$ 30.17万 - 项目类别:
Improving Outcomes in Pharmacotheraphy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7126934 - 财政年份:2005
- 资助金额:
$ 30.17万 - 项目类别:
Improving Outcomes in Pharmacotherapy of Social Phobia
改善社交恐惧症药物治疗的效果
- 批准号:
7688133 - 财政年份:2005
- 资助金额:
$ 30.17万 - 项目类别: